Raloxifene Hydrochloride (USP)
Introduction
Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. Evistais the common commercial brand name and it was developed by Eli Lilly and Company.
We have followed the experimental conditions in the current Raloxifene hydrochloride USP monograph (USP38-NF33):
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!